These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 15250677)

  • 1. Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinase Abl transcript in the treatment of chronic myeloid leukaemia.
    Knight GW; McLellan D
    Br J Biomed Sci; 2004; 61(2):103-11. PubMed ID: 15250677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D
    Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
    Sawyers CL
    Semin Hematol; 2001 Jul; 38(3 Suppl 8):15-21. PubMed ID: 11526597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
    von Bubnoff N; Peschel C; Duyster J
    Leukemia; 2003 May; 17(5):829-38. PubMed ID: 12750693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
    Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T
    Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
    Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
    Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
    Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
    Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
    Melo JV; Chuah C
    Hematology Am Soc Hematol Educ Program; 2008; ():427-35. PubMed ID: 19074121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.
    O'Dwyer ME; Druker BJ
    Lancet Oncol; 2000 Dec; 1():207-11. PubMed ID: 11905636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic myelogenous leukaemia--new therapeutic principles.
    O'Dwyer ME; Druker BJ
    J Intern Med; 2001 Jul; 250(1):3-9. PubMed ID: 11454136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics.
    Sawyers CL
    Cancer Cell; 2002 Feb; 1(1):13-5. PubMed ID: 12086882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preclinical and clinical profile of imatinib mesilate, a potent protein-tyrosine kinase inhibitor for CML therapy].
    Toga W; Kondo M; Tokoro A
    Nihon Yakurigaku Zasshi; 2003 Feb; 121(2):119-28. PubMed ID: 12616857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
    Druker BJ
    Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia.
    Manley PW; Cowan-Jacob SW; Mestan J
    Biochim Biophys Acta; 2005 Dec; 1754(1-2):3-13. PubMed ID: 16172030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms and implications of imatinib resistance mutations in BCR-ABL.
    Nardi V; Azam M; Daley GQ
    Curr Opin Hematol; 2004 Jan; 11(1):35-43. PubMed ID: 14676625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy.
    Druker BJ
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S70-6. PubMed ID: 12528776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP; Croom KF; Goa KL
    BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
    Nakajima M; Toga W
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular-target therapy of Ph-positive leukemia by imatinib (tyrosine kinase inhibitor)].
    Tauchi T; Ohyashiki K
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1065-70. PubMed ID: 12938259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.